company background image
AVE

Avecho BiotechnologyASX:AVE Stock Report

Market Cap

AU$33.1m

7D

0%

1Y

80.0%

Updated

26 Oct, 2021

Data

Company Financials
AVE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AVE Overview

Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally.

Avecho Biotechnology Competitors

Merck

NYSE:MRK

US$206.7b

Fresenius SE KGaA

XTRA:FRE

€22.9b

Teva Pharmaceutical Industries

NYSE:TEVA

US$11.2b

DURECT

NasdaqCM:DRRX

US$261.6m

Price History & Performance

Summary of all time highs, changes and price drops for Avecho Biotechnology
Historical stock prices
Current Share PriceAU$0.018
52 Week HighAU$0.01
52 Week LowAU$0.045
Beta1.96
1 Month Change0%
3 Month Change-5.26%
1 Year Change80.00%
3 Year Change-35.71%
5 Year Change-43.75%
Change since IPO-96.25%

Recent News & Updates

Jul 14
We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. Indeed, Avecho Biotechnology ( ASX:AVE...

Mar 23
We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

AVEAU PharmaceuticalsAU Market
7D0%-1.0%0.8%
1Y80.0%8.7%24.4%

Return vs Industry: AVE exceeded the Australian Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: AVE exceeded the Australian Market which returned 24.4% over the past year.

Price Volatility

Is AVE's price volatile compared to industry and market?
AVE volatility
AVE Beta1.96
Industry Beta1.3
Market Beta1

Stable Share Price: AVE is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: AVE's weekly volatility has decreased from 25% to 13% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1992n/aPaul Gavinhttps://avecho.com.au

Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Fundamentals Summary

How do Avecho Biotechnology's earnings and revenue compare to its market cap?
AVE fundamental statistics
Market CapAU$33.05m
Earnings (TTM)-AU$3.50m
Revenue (TTM)AU$453.54k

75.0x

P/S Ratio

-9.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVE income statement (TTM)
RevenueAU$453.54k
Cost of RevenueAU$195.39k
Gross ProfitAU$258.14k
ExpensesAU$3.76m
Earnings-AU$3.50m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0019
Gross Margin56.92%
Net Profit Margin-771.69%
Debt/Equity Ratio0%

How did AVE perform over the long term?

See historical performance and comparison

Valuation

Is Avecho Biotechnology undervalued compared to its fair value and its price relative to the market?

5.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AVE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AVE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AVE is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: AVE is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVE is overvalued based on its PB Ratio (5.6x) compared to the AU Pharmaceuticals industry average (3.7x).


Future Growth

How is Avecho Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avecho Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Avecho Biotechnology performed over the past 5 years?

53.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVE is currently unprofitable.

Growing Profit Margin: AVE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVE is unprofitable, but has reduced losses over the past 5 years at a rate of 53.1% per year.

Accelerating Growth: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: AVE has a negative Return on Equity (-58.8%), as it is currently unprofitable.


Financial Health

How is Avecho Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: AVE's short term assets (A$6.1M) exceed its short term liabilities (A$590.3K).

Long Term Liabilities: AVE's short term assets (A$6.1M) exceed its long term liabilities (A$60.9K).


Debt to Equity History and Analysis

Debt Level: AVE is debt free.

Reducing Debt: AVE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AVE has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 36% each year.


Dividend

What is Avecho Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVE's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Paul Gavin

1.42yrs

Tenure

AU$470,788

Compensation

Dr. Paul Gavin, BSc (Hons), PhD serves as Chief Executive Officer of Avecho Biotechnology Limited (formerly known as Phosphagenics Limited) since May 01, 2020 and served as its Chief Scientific Officer unt...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD352.91K) is about average for companies of similar size in the Australian market ($USD301.38K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AVE's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: AVE's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.9%.


Top Shareholders

Company Information

Avecho Biotechnology Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Avecho Biotechnology Limited
  • Ticker: AVE
  • Exchange: ASX
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$33.050m
  • Shares outstanding: 1.84b
  • Website: https://avecho.com.au

Number of Employees


Location

  • Avecho Biotechnology Limited
  • 2A Westall Road
  • Unit A8
  • Clayton
  • Victoria
  • 3168
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 07:01
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.